The Widening Gulf in Pharmaceutical Dealmaking
Executive Summary
The pharma-to-biotech dealmaking drought, which began in 1999, continues in 2000. Drug companies have been distracted by consolidation and by their focus on later-stage products; biotechs have found funding through the capital markets. Instead, there have been plenty of biotech-to-biotech deals--little cash changes hands, but each partner's technology enables the other to reach later-stages of development, and thus keep a higher proportion of the drug's upside, granted the other has the cash to develop it.
You may also be interested in...
‘Clear’ Is In The Eye Of The Beholder, New York, CRN Argue In Age-Restricted Sales Litigation
CRN’s request for clarification, as it continues litigating complaint in US District Court for Southern New York, highlights what it contends is vague and overly general language in the legislation passed in October with a 22 April effective date.
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.